|
Market Cap (18-May) $1,668,273,536 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 76.34 |
EPS 1.09 |
NEU released this announcement to the ASX on 7 December 2021, 9:48. The announcement is marked as price sensitive, and is 5 page(s) in length and 174.6kb in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.002% short sold according to ASIC data. It was ranked the 673rd most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Positive topline results from Phase 3 trial in Rett syndrome | 7 December 2021, 9:48 |
| Neuren presenting at Bell Potter Healthcare Conference | 10 November 2021, 8:58 |
| Q3 2021 quarterly activity and cash flow report | 28 October 2021, 9:39 |
| Neuren receives feedback on IND for Phelan-McDermid syndrome | 21 October 2021, 12:51 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 